-
Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates2024 Blood Advances article Biochemistry, Genetics and Molecular Biology Blood disorders and treatments Open access
Ana Rita Da Fonseca, Caio Cesar Justino, Vinícius Campos de Molla, Patrícia Eiko Yamakawa, Iara Baldim Rabelo, Louise Arnold, +10 more
0citations